Question 1

What is combined oxidative phosphorylation defect type 7?

Accepted Answer

Combined oxidative phosphorylation defect type 7 is a rare mitochondrial condition that affects energy production in cells, particularly impacting the nervous system and muscles. It is caused by alterations in the MTRFR gene, which plays a role in mitochondrial protein synthesis. The disorder typically presents in infancy or early childhood, with affected children initially developing normally before symptoms emerge. The condition is very rare, affecting fewer than 1 in a million people, and its progression can be variable.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 7?

Accepted Answer

After a period of apparently typical early development, affected children experience a phase of developmental regression marked by loss of previously acquired skills. Characteristic clinical features include global developmental delay, increased circulating lactate levels, and prominent ocular findings such as optic atrophy, nystagmus, and ptosis. Many children also develop facial diplegia, ataxia, and areflexia, while additional features like dysphagia, dysarthria, and reduced mastication may be observed in some cases. Not all individuals experience all features, and severity varies considerably, with differences in both cognitive and neurological presentations across affected individuals.

Question 3

What causes combined oxidative phosphorylation defect type 7?

Accepted Answer

The underlying cause of combined oxidative phosphorylation defect type 7 is a defect in the MTRFR gene, which is essential for proper mitochondrial protein synthesis. This disruption impairs the cell’s ability to generate energy efficiently, particularly affecting high-energy systems such as the brain and muscles. The condition is inherited in an autosomal recessive pattern, meaning that an affected individual has inherited two copies of the altered gene, one from each parent. Families with a shared common ancestry may have an increased likelihood of both parents carrying the same rare genetic change, and genetic counseling is recommended to discuss recurrence risks and family planning options. Associated genes include MTRFR.

Question 4

How is combined oxidative phosphorylation defect type 7 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 7 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 7?

Accepted Answer

combined oxidative phosphorylation defect type 7 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 7 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in the MTRFR gene. In addition to genetic testing, a careful clinical evaluation that considers the child’s developmental history and the presence of characteristic features such as developmental regression, ocular abnormalities, and neuromuscular symptoms is essential. Since the symptoms can overlap with other conditions, molecular testing is crucial to establish a definitive diagnosis.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 7?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as there are no approved treatments specific to this condition. Treatment is tailored to the individual and typically involves a multidisciplinary team that may include neurologists, ophthalmologists, and physical therapists. Regular surveillance is an essential part of long-term care to monitor developmental progress and address complications early. Patients are encouraged to discuss treatment options and supportive therapies with their healthcare team to determine the most appropriate approach for their situation, and genetic counseling is recommended for families to better understand the inheritance pattern.

Question 8

What complications can arise from combined oxidative phosphorylation defect type 7?

Accepted Answer

Complications from combined oxidative phosphorylation defect type 7 can include developmental regression, which means that children may lose skills they previously acquired. Additionally, some children may experience motor decline as they grow older. Regular monitoring and supportive care are important to manage these complications and improve quality of life.

Question 9

How does combined oxidative phosphorylation defect type 7 affect daily life for my child?

Accepted Answer

Daily life for a child with combined oxidative phosphorylation defect type 7 can be challenging due to developmental delays and possible motor difficulties. Children may need assistance with activities like eating, speaking, and moving around. Supportive therapies, such as physical therapy and speech therapy, can help improve their daily functioning and overall well-being.

Question 10

What is the long-term prognosis for someone with combined oxidative phosphorylation defect type 7?

Accepted Answer

The long-term prognosis for someone with combined oxidative phosphorylation defect type 7 varies widely. Many individuals may live into adulthood, but their health can be affected by the severity of symptoms and the age at which they were diagnosed. With proper care and support, many families see improvements in quality of life and health outcomes over time.

Question 11

What specialists should we consult for combined oxidative phosphorylation defect type 7?

Accepted Answer

For combined oxidative phosphorylation defect type 7, it is important to consult a team of specialists. This may include neurologists for neurological symptoms, ophthalmologists for eye-related issues, and physical therapists for motor skills. Working with a multidisciplinary team can help address the various challenges associated with this condition and provide comprehensive care.

Organ System	Phenotype Count	Example Features
Brain and nerves	7	Polyneuropathy, Elevated brain lactate level by MRS, Ataxia
Eyes	5	Strabismus, Nystagmus, Ptosis
Muscles	4	Low muscle tone (hypotonia), Muscle weakness, Skeletal muscle atrophy
Lab test results	4	Decreased activity of mitochondrial ATP synthase complex, Increased circulating lactate concentration, Decreased activity of mitochondrial complex I
Head and neck	2	Facial diplegia, Facial paralysis
Growth and development	1	Failure to thrive
Bones and joints	1	Skeletal muscle atrophy
Digestive system	1	Difficulty swallowing (dysphagia)

Kisho

combined oxidative phosphorylation defect type 7

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

combined oxidative phosphorylation defect type 7

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 7?

What are the symptoms of combined oxidative phosphorylation defect type 7?

What causes combined oxidative phosphorylation defect type 7?

How is combined oxidative phosphorylation defect type 7 inherited?

How rare is combined oxidative phosphorylation defect type 7?

How is combined oxidative phosphorylation defect type 7 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 7?

What complications can arise from combined oxidative phosphorylation defect type 7?

How does combined oxidative phosphorylation defect type 7 affect daily life for my child?

What is the long-term prognosis for someone with combined oxidative phosphorylation defect type 7?

What specialists should we consult for combined oxidative phosphorylation defect type 7?